Quikin CD19-CART in Patients With r/r B-cell Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 18
Summary
- Conditions
- B Cell Lymphoma
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: Patients will receive one of the three doses of 2*10^6/kg, 4*10^6/kg,6*10^6/kg.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 65 years
- Gender
- Both males and females
Description
Quikin CD19-CART is a kind of chimeric antigen T cell targeting CD19 with both CD19-CAR gene integration and also PD1 knockout by one-step gene-editing. After completion of study treatment, subject participation for this study will be followed up to 15 years after completion of study treatment.
Quikin CD19-CART is a kind of chimeric antigen T cell targeting CD19 with both CD19-CAR gene integration and also PD1 knockout by one-step gene-editing. After completion of study treatment, subject participation for this study will be followed up to 15 years after completion of study treatment.
Tracking Information
- NCT #
- NCT04213469
- Collaborators
- First Affiliated Hospital of Zhejiang University
- Investigators
- Principal Investigator: He Huang, Prof the First Affliated Hospital, Zhejiang University
Get Well Soon